Cancer Research UK Leads Global Trial of Rare Adrenal Gland Cancer Therapy
In a landmark development for oncology, Cancer Research UK is leading a consortium of international partners to launch a global Phase II clinical trial targeting rare adrenal gland cancer.
The biotechnology company Cytovation and the Norwegian Cancer Society (NCS) have joined forces with Cancer Research UK for the trial, which focuses on patients with advanced adrenocortical carcinoma (ACC), a rare and highly aggressive form of the disease www.ddw-online.com .
The Strategic Imperative: “People living with ACC deserve better treatment options and we are pleased the CLARITY study has reached this exciting stage,” stated Dr. Lars Erwig, Director of the Centre for Drug Development at Cancer Research UK. “We thank our partners... for their ongoing collaboration to help bring us closer to a world where people with rare cancers live longer, better lives.” www.ddw-online.com
The trial will evaluate Cytovation’s synthetic peptide therapy, CY-101 (getacatetide) www.ddw-online.com . This novel intratumoural peptide immunotherapy is specifically designed to convert immune-resistant ‘cold’ tumours, such as ACC, into immune-active ‘hot’ tumours www.ddw-online.com .
The therapy operates by stimulating local immune activation directly within the tumour microenvironment, while simultaneously inhibiting the Wnt/β-catenin signalling pathway, which is a key driver of immunotherapy resistance in cancers like ACC www.ddw-online.com .
The urgency for this monumental breakthrough is underscored by current statistics: approximately 350 people in the UK are diagnosed with ACC annually, and with limited treatment options, around 130 individuals succumb to the disease each year www.ddw-online.com .
Global Trajectory: This international collaboration represents a paradigm shift in rare cancer research, pooling resources and expertise to accelerate the delivery of life-saving therapies to patients with the most critical unmet medical needs.
Official Source Verification
Drug Discovery World officially documented this major medical research milestone on July 13, 2026, providing comprehensive insights into the trial's methodology and collaborative framework.
For the complete trial protocol, partner statements, and the full executive summary of the CLARITY study, please consult the primary source publication.
Comments (0)
No comments yet. Be the first to share your thoughts!
Want to join the discussion?
Please log in to post a comment.
Login NoworCreate an Account